EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease

Stephanie A Schultz, Yiwen Rao, Lei Liu, Beth Ostaszewski, Amirah K Anderson, Wai-Ying Wendy Yau, Zahra Shirzadi, Brian A Gordon, Jason Hassenstab, John C Morris, Richard J Perrin, Ricardo F Allegri und 15 weitere

Alzheimer's & Dementia · 2026

DOI: 10.1002/alz.71049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Stephanie A Schultz und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: tau Proteins, Alzheimer Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Davis APP program, Korea Health Industry Development Institute, Alzheimer's Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Tau species lacking truncation of the N‐terminal region, including plasma N‐terminal tau fragment 1 (NT1), have been previously associated with cognitive decline, neurodegeneration, and tau pathology in late‐onset sporadic Alzheimer's disease (AD). METHODS Here, we examined cross‐sectional and longitudinal plasma NT1 as a possible predictor of cognitive, clinical, and core AD biomarker trajectories in autosomal dominant AD (ADAD). RESULTS NT1 levels in ADAD mutation carriers (MC; n = 132) increased across the disease continuum, compared to non‐carriers (NC; n = 75), becoming elevated about a decade prior to estimated symptom onset. Cross‐sectional and longitudinal NT1 levels in MC were associated with clinical, cognitive, and biomarker changes. NT1 increases continued in symptomatic phases of disease, a distinct trajectory from that seen with CSF p‐tau217 and other phospho‐tau species. DISCUSSION Together, our results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related clinical, cognitive, and biomarker outcomes. Highlights Leveraging a deeply phenotyped cohort of individuals carrying a pathogenic variant for autosomal dominant Alzheimer's disease (ADAD) and their non‐carrier family members, our results suggest that plasma N‐terminal tau fragment 1 (NT1) levels mirrored changes in clinical, cognitive, and neurodegenerative measures in ADAD, particularly in late asymptomatic and early symptomatic phases of disease. NT1 levels correlated with cerebrospinal fluid (CSF) measures of tau pathology but less so with CSF or imaging measures of β‐amyloid pathology. Together with previous supportive findings in preclinical and symptomatic sporadic AD, these results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related tau pathology and neurodegeneration across a wide spectrum of disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAlzheimer DiseaseNeurodegenerative DiseasesHumansBiomarkersFemaleMaleCross-Sectional StudiesMiddle AgedLongitudinal StudiesPeptide FragmentsAgedMutation

Stichwörter der Autor:innen

ADADbiomarkerneurodegenerationtauopathy

Substanzen

tau ProteinsBiomarkersPeptide Fragments

Autor:innen und Institutionen

  • Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Division of Basic Neuroscience Research, Ann Romney Center for Neurologic Diseases, Boston, Massachusetts, USA.
  • Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
  • Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology, Instituto Neurológico Fleni, Buenos Aires, Argentina.

Förderung

  • Davis APP program
  • Korea Health Industry Development Institute
  • Alzheimer's Association
  • National Institute on Aging (NIA), the Alzheimer's Association
  • NIA NIH HHS
  • The Dominantly Inherited Alzheimer Network
  • Raul Carrea Institute for Neurological Research
  • Korea Dementia Research Center

Zitieren

APA

Schultz, S. A., Rao, Y., Liu, L., Ostaszewski, B., Anderson, A. K., Yau, W. W., Shirzadi, Z., Gordon, B. A., Hassenstab, J., Morris, J. C., Perrin, R. J., Allegri, R. F., Barthélemy, N. R., Fox, N., Day, G. S., Jucker, M., Levey, A. I., Levin, J., Mori, H., …, & and the Dominantly Inherited Alzheimer's Network (2026). Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71049

Vancouver

Schultz SA, Rao Y, Liu L, Ostaszewski B, Anderson AK, Yau WW, et al. Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71049

BibTeX
@article{Schultz2026,
  author = {Schultz, Stephanie A and Rao, Yiwen and Liu, Lei and Ostaszewski, Beth and Anderson, Amirah K and Yau, Wai-Ying Wendy and Shirzadi, Zahra and Gordon, Brian A and Hassenstab, Jason and Morris, John C and Perrin, Richard J and Allegri, Ricardo F and Barthélemy, Nicolas R and Fox, Nick and Day, Gregory S and Jucker, Mathias and Levey, Allan I and Levin, Johannes and Mori, Hiroshi and Salloway, Stephen and Schofield, Peter and McDade, Eric and Sperling, Reisa A and Bateman, Randall J and Selkoe, Dennis J and Chhatwal, Jasmeer P and and the Dominantly Inherited Alzheimer's Network, and the Dominantly Inherited Alzheimer's Network},
  title = {Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  doi = {10.1002/alz.71049}
}
Kostenlos starten →